HK Midday: HSI Gains Nearly 1% as Gold Stocks Surge; Kuaishou Tumbles Over 10% Post-Earnings
I'm LongbridgeAI, I can summarize articles.HSI rose nearly 1% on Aug 20, led by a broad rally in gold miners as bullion prices soared. Lingbao Gold jumped over 11%. Kuaishou slumped nearly 11% after earnings, while pharma and NEV sectors advanced.
Hong Kong's three major indices climbed in tandem on August 20 morning trading. As of press time, the Hang Seng Index added 0.74% or 189.85 points to 25,684.92; the Hang Seng China Enterprises Index rose 1.02% to 8,557.82; and the Hang Seng TECH Index gained 1.05% to 4,731.25. Gold stocks led the market with a broad-based surge, while pharmaceutical and new energy vehicle sectors also strengthened. Kuaishou tumbled over 10% after its earnings report, weighing on select tech names.
Gold Stocks Rally Across the Board; Lingbao Gold Jumps Over 11%
As of press time, Lingbao Gold (03330.HK) surged over 11% to HK$24.58; Zhaojin Mining (01818.HK) rallied nearly 11% to HK$26.36; China Gold International Resources (02099.HK) climbed nearly 8% to HK$247.80; and CMOC Group (03993.HK) rose nearly 4% to HK$17.14.
The U.S. Treasury announced a significant expansion of its long-term bond buyback program to stabilize the market, sending Treasury yields lower and the dollar index to its weakest since late May. Spot gold surged over 4% overnight. Meanwhile, the Fed's July meeting minutes signalled a hawkish tilt, fuelling safe-haven demand for gold and further supporting bullion prices.
Pharma Stocks Strengthen; CSPC Pharmaceutical Soars Over 14%
As of press time, CSPC Pharmaceutical Group (01093.HK) soared over 14% to HK$9.91 on turnover exceeding HK$2 billion; WuXi Biologics (02269.HK) jumped nearly 6% to HK$50.70; and WuXi AppTec (02268.HK) advanced 3% to HK$70.10.
Overnight, Moderna and Merck's jointly developed mRNA personalized cancer vaccine delivered positive results in a Phase III clinical trial, sending Moderna shares surging nearly 180% in a single session. The Nasdaq Biotechnology Index soared 6.4%, significantly lifting sentiment across global pharmaceutical stocks.
Kuaishou Slumps Over 10% Post-Earnings; Tech Stocks Diverge
As of press time, Kuaishou-W (01024.HK) tumbled nearly 11% to HK$33.68 on turnover exceeding HK$3.8 billion. The company reported Q2 net profit of RMB3.152 billion, down 36% year-on-year but slightly ahead of expectations. It guided full-year capex of RMB26 billion, with Chairman Cheng Yixiao cautioning that ongoing investments and external challenges will weigh on near-term profitability. Weimob (02013.HK) slumped nearly 10% to HK$1.00. Among large-cap tech names, Tencent (00700.HK) rose 1.4%, Alibaba (09988.HK) added 0.6%, Meituan (03690.HK) gained 1.3%, Xiaomi (01810.HK) advanced over 3%, and JD.com (09618.HK) climbed 2.6%.
NEV Sector Rises Broadly; Li Auto Gains 5%
As of press time, Li Auto-W (02015.HK) rose 5% to HK$50.30; NIO-SW (09866.HK) gained over 4% to HK$36.36; XPeng-W (09868.HK) added 3% to HK$47.32; and BYD Company (01211.HK) advanced 2.5% to HK$91.60. Property stocks also rebounded in morning trading, with China Resources Land (01109.HK) up 4%, China Overseas Land & Investment (00688.HK) up nearly 3%, and Sun Hung Kai Properties (00016.HK) up nearly 3%.
